News Conference News ACC 2023 Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better Shelley Wood March 10, 2023
News Conference News ACC 2022 Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events Todd Neale April 04, 2022
News Conference News ACC 2021 Low 1-Year Stroke Risk After Commercial Watchman Use Todd Neale May 15, 2021
News Conference News ACC 2021 High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE Michael O'Riordan May 15, 2021
News Conference News ACC 2020 LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout Todd Neale April 06, 2020
News Conference News ACC 2020 A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI Todd Neale March 29, 2020
News Conference News ACC 2019 No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel Shelley Wood March 19, 2019
News Conference News ACC 2018 PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO Shelley Wood March 15, 2018
News Conference News ACC 2017 RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest Yael L. Maxwell March 20, 2017
News Conference News ACC 2017 Post-TAVR, Nearly a Quarter of Patients Show New Signs of Silent Cerebral Microbleeds on MRI Caitlin E. Cox March 20, 2017
News Conference News ACC 2017 Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit Todd Neale March 19, 2017
News Conference News ACC 2016 Cardioband Transcatheter Mitral Annulus Repair Appears Safe, Effective in Functional MR Shelley Wood April 07, 2016
News Conference News ACC 2015 Follow-up TAVR Studies Reassure About Valve Durability, Outcomes Todd Neale March 15, 2015
News Conference News ACC 2015 Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients Todd Neale March 14, 2015
News Conference News ACC 2014 CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks L.A. McKeown March 31, 2014
News Conference News ACC 2012 ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released Yael L. Maxwell April 02, 2012
News Conference News ACC 2012 PARTNER: TAVR Remains as Effective as Surgery at 2 Years March 26, 2012
News Conference News ACC 2012 EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants March 25, 2012
News Conference News ACC 2012 Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES Jason Kahn March 24, 2012